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ABSTRACT
CDC are exotoxins secreted by many Gram-positive
bacteria that bind cholesterol and oligomerize to form
pores in eukaryotic cell membranes. We demonstrate
that CDC TLO induces caspase-1 cleavage and the
rapid release of IL-1 from LPS-primed murine BMDM.
IL-1 secretion depends on functional toxin pore forma-
tion, as free cholesterol, which prevents TLO binding to
cell membranes, blocks the cytokine release. Secretion
of the mature forms of IL-1 and caspase-1 occurs only
at lower TLO doses, whereas at a higher concentration,
cells release the biologically inactive proforms. IL-1 re-
lease at a low TLO dose requires potassium efflux, cal-
cium influx, and the activities of calcium-independent
PLA2, caspase-1, and cathepsin B. Additionally, mature
IL-1 release induced by a low TLO dose is dependent
on the NLRP3 inflammasome, and pro-IL-1 release in-
duced by a high TLO dose occurs independently of
NLRP3. These results further elucidate a mechanism of
CDC-induced IL-1 release and suggest a novel, im-
mune evasion strategy in which IL-1-containing macro-
phages might release primarily inactive cytokine follow-
ing exposure to high doses of these toxins. J. Leukoc.
Biol. 86: 1227–1238; 2009.
Introduction
CDC are a class of protein exotoxins that are secreted by over
20 species of Gram-positive bacteria [1, 2]. Individual subunits
bind to cholesterol in eukaryotic cell membranes and oli-
gomerize to form transmembrane pores up to 30 nm in size
[1–5]. Forty to 80 CDC monomers assemble into a pre-pore
complex before membrane insertion and final pore conver-
sion, which results in osmotic imbalance that may lead to cell
death. Mice injected i.v. with 100 pmol purified forms of sev-
eral different CDC underwent almost immediate death [6],
demonstrating the potent biological activities of these toxins.
PLY-deficient Streptococcus pneumoniae have reduced virulence
in mice, supporting a potential role for such toxins in bacte-
rial pathogenesis [7, 8]. In contrast, immunization of mice
with ALO or a genetic toxoid does not protect against Bacillus
anthracis infection [9], suggesting that for some CDC-bearing
pathogens, the toxin plays a less-important role. It should be
noted that at least one CDC, LLO, has a specialized role in
allowing escape of Listeria from the phagosome into the cy-
tosol and is maximally active at acidic pH [10, 11]. Although
CDC such as ALO can substitute for LLO when manipulated
experimentally [12], most CDC do not show a marked pH de-
pendence and are believed to function primarily extracellu-
larly following secretion by bacteria, acting on adjacent cells in
the infected host.
Although all eukaryotic cells are susceptible to toxin-in-
duced lysis, the amounts required for killing vary widely be-
tween cell types [13]. This may be a result of a differential
ability of distinct cell types to repair membranes damaged by
pores. Evidence for membrane repair after toxin damage has
been obtained by measuring cytoplasmic ATP levels, which
decrease drastically after exposure to sublethal concentrations
of toxin before a return to normal levels [14, 15]. At higher
lytic levels of toxin, recovery of ATP levels is not observed. The
mechanism of repair involves removal of pores from the
plasma membrane via an endocytic process [16]. Cells that
have been exposed to sublytic doses of toxin and then recover
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may be altered phenotypically, and there are numerous exam-
ples of such sublethal effects of CDC [1].
In immune cells, exposure to CDC toxins at concentrations
that are not lytic have been observed to induce release of cyto-
kines and chemokines [1, 17], and cytokine and chemokine
secretion is particularly important for the recruitment and acti-
vation of inflammatory immune cells to the local site of bacte-
rial infection. One major cytokine family that plays a role in
the inflammation process is the IL-1 family. Included in this
family are IL-1 and IL-1, which are released upon interac-
tion of cells with CDC. Specifically, LLO induces the release of
IL-1 from murine macrophages [18], and SLO and PLY
cause the secretion of IL-1 from human monocytes [19, 20].
The mechanism by which CDC induce release of IL-1 has not
been fully characterized to date.
IL-1 and IL-1, as well as IL-18 and IL-33, are stored inside
cells, such as macrophages and dendritic cells, as precursors
whose synthesis is induced by exposure to TLR ligands (signal
1) [21]. Unlike many other cytokines, efficient release requires
exposure of cells to a second stimulus to initiate processing
and the nonclassical secretion of the active cytokine. The sec-
ond stimuli lead to the activation of inflammasome complexes,
which consist of members of the NLR family for the activation
of inflammatory caspases such as caspase-1 (for a review, see
refs. [22–24]). The best-known examples of these caspase-1-
activating platforms are the NLRP1, NLRP3, and NLRC4 in-
flammasomes, which lead to the processing of the pro-form of
IL-1 to its mature form. To date, multiple second stimuli for
these various inflammasomes have been identified (for a re-
view, see ref. [23]), and select ones will be discussed below.
One of the best-studied second stimuli is ATP, which acts by
binding to the purinergic receptor P2X7, initiating calcium
influx and potassium efflux via its ion channel function [25].
Calcium is also released from intracellular stores during this
process and contributes to cytokine release [26]. Potassium
efflux leads to activation of calcium-independent phospho-
lipase (iPLA2) [27] and the NLRP3 inflammasome, which con-
tains dimeric caspase-1, adaptor apoptosis-associated speck-like
protein containing a C-terminal caspase recruitment domain,
and NLRP3 (also known as cryopyrin or NALP3) [28]. Activa-
tion of this inflammasome leads to cleavage of caspase-1,
which has been shown to cleave inactive pro-IL-1 to generate
active, mature IL-1 for release from the cell. Additionally,
P2X7 activation causes recruitment of pannexin-1 protein to
form a nonselective pore for passage of molecules up to 900
Da across membranes [29, 30]. This pannexin-1 pore is
thought to allow ion fluxes as well as the passage of bacterial
products from inside endosomes or phagosomes into the cy-
tosol for the subsequent activation of one or more inflamma-
some complexes [31].
An additional stimulus that can activate the NLRP3 inflam-
masome and initiate IL-1 release is potassium ionophore ni-
gericin, which exerts its effects primarily through a potassium
efflux mechanism [32]. Much like ATP, it also relies on the
activity of caspase-1 but acts independently of P2X7 [33].
Other stimuli inducing IL-1 release from myeloid cells
through a NLRP3 and caspase-1-dependent mechanism in-
clude uric acid crystals [34], silica crystals [35, 36], aluminum
salt crystals [35], and amyloid- fibrils [37]. All of these can be
phagocytosed by macrophages and appear to disrupt lyso-
somes, resulting in leakage of their contents into the cytosol
[38]. It was reported recently that cathepsin B is required for
release of IL-1 following stimulation with silica crystals, alumi-
num salt crystals, or amyloid- [35, 37], which supports a sce-
nario in which mislocalized cathepsin B is involved in aspects of
NLRP3 inflammasome activation or subsequent IL-1 release. In
fact, other groups have shown that cathepsin B activates
caspase-11, which in turn, acts as an upstream activator of
caspase-1 [39, 40].
In this report, we describe the mechanism of rapid IL-1
release after exposure of LPS-primed murine BMDM to the
CDC TLO. Cytokine release occurs maximally within 2 h of
initial treatment with little additional release occurring by 20 h
post-treatment. Although TLO-induced IL-1 secretion is de-
pendent on functional toxin pore formation, this alone is not
sufficient for the processing and secretion of IL-1. Lower
TLO doses are required for release of mature IL-1, as well as
for the cleavage and release of mature caspase-1, as opposed
to higher doses that enable the release of the inactive pro-IL-
1. Similarly to ATP and nigericin, TLO-induced release is
dependent on potassium efflux, calcium influx, and the activi-
ties of iPLA2, caspase-1, and cathepsin B, as determined by
pharmacological inhibition. Moreover, TLO-induced release of
mature IL-1 is dependent on the NLRP3 inflammasome and
independent of the NLRC4 inflammasome, based on studies
using BMDM deficient in NLRP3 or NLRC4. In summary, we




TLO was obtained from Biomol International (Plymouth Meeting, PA,
USA). Toxin was reduced with 10 mM DTT (Sigma-Aldrich, St. Louis, MO,
USA) for 10 min, 37°C, before use, unless indicated, and untreated control
samples were incubated in the same buffer lacking toxin. ATP, nigericin,
LPS, cholesterol, and pepstatin A were purchased from Sigma-Aldrich;
z-VAD-fmk/pan-caspase inhibitor VI, BAPTA-AM, Z-FF-fmk/cathepsin L in-
hibitor I, and CA-074 Me/cathepsin B inhibitor IV from EMD Biosciences
(Gibbstown, NJ, USA); Ac-YVAD-cmk/caspase-1 inhibitor II and BEL from
Axxora, LLC (San Diego, CA, USA); and Triton X-100 from Fisher Scientific
(Pittsburgh, PA, USA). Purified anti-mouse IL-1 and IL-1 capture antibod-
ies, biotin-conjugated anti-mouse IL-1 and IL-1 detection antibodies, and
rIL-1 were acquired from eBioscience (San Diego, CA, USA). Purified and
biotin-conjugated anti-mouse TNF- antibodies, rTNF-, rIL-1, avidin-HRP,
and TMB were obtained from Biolegend (San Diego, CA, USA).
BMDM preparation
The following protocol was adapted from ref. [41]. Tibiae and femurs from
wild-type (gifts from Dr. Lisa Borghesi, University of Pittsburgh, PA, USA),
NLRP3/, or NLRC4/ C57BL/6 mice were collected. BM cells were
extracted using a 27-gauge needle and passed through a 21-gauge needle
to obtain a homogenous mixture. Cells were plated in petri dishes (Day 1)
in DMEM (Mediatech, Inc., Herndon, VA, USA), supplemented with 20%
Gemcell™ FBS (Gemini Bio-Products, West Sacramento, CA, USA), 2 mM
L-glutamine, 500 U penicillin/500 g streptomycin (Lonza, Inc., Walkers-
ville, MD, USA), 1 mM sodium pyruvate (MP Biomedicals, Solon, OH,
USA), and 30% L cell supernatant, which was generated by incubating L
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cell fibroblasts (CCL-1 from American Type Culture Collection, Manassas,
VA, USA) in DMEM, supplemented with 10% Gemcell™ FBS, 2 mM L-glu-
tamine, 500 U penicillin/500 g streptomycin, 1 nonessential amino ac-
ids (Irvine Scientific, Santa Ana, CA, USA), and 1 mM sodium pyruvate
until confluent. Supernatant was collected and filtered through a 0.22-um
filter. Differentiation media for BMDM were changed every 3–4 days, and
BMDM were used for experiments on Days 8–22. For experiments, BMDM
were cultured in IMDM (Lonza, Inc.) containing 10% Gemcell™ FBS, 2
mM L-glutamine, and 500 U penicillin/500 g streptomycin.
Western blotting
BMDM (2106; plated the day before) were treated for 4 h in serum-con-
taining IMDM with 1 g/ml LPS and various concentrations of TLO or
were left untreated. In some cases, following LPS priming, BMDM were
incubated for 30 min in serum-free media with DTT control buffer, various
doses of TLO, 3 mM ATP, 20 M nigericin, or 1% Triton X-100. Where
indicated, 1 ml supernatants were collected and TCA/cholic acid-precipi-
tated as described by Qu and colleagues [42]. Cells were harvested,
washed, and lysed or lysed directly in wells with Nonidet P-40 lysis buffer
containing a protease inhibitor cocktail (Sigma-Aldrich). Bradford assay
(Bio-Rad, Hercules, CA, USA) was conducted to determine protein concen-
tration of lysates, and 20–50 g protein lysate was run on SDS-PAGE gels
along with concentrated supernatants (where indicated). Proteins were
transferred to polyvinylidene difluoride membrane using Towbin buffer
transfer or the iBlot™ system (Invitrogen, Carlsbad, CA, USA) and probed
for IL-1 with mouse anti-IL-1 primary antibody (3ZD; National Cancer
Institute Biological Resources Branch, Frederick Cancer Research and De-
velopment Center, Frederick, MD, USA) and goat anti-mouse IgG-HRP sec-
ondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) using
the SNAP i.d.™ system (Millipore, Bedford, MA, USA). Membranes were
also probed for caspase-1 with rabbit anti-caspase-1 primary antibody and
donkey anti-rabbit IgG-HRP secondary antibody (Biolegend). In some
cases, the same blot was stripped with Restore Plus Western blot stripping
buffer (Thermo Scientific, Rockville, MD, USA), according to the manufac-
turer’s protocol, and reprobed with rabbit anti--actin primary antibody
(Biolegend) and donkey anti-rabbit IgG-HRP secondary antibody. Western
blotting luminol reagent (Santa Cruz Biotechnology) was applied, and
membranes were imaged and analyzed (densitometry) with Kodak Image
Station 4000MM (Molecular Imaging Systems, Carestream Health, Inc.,
Rochester, NY, USA). The net intensity of a single IL-1 protein band in a
supernatant sample is expressed as a percentage of the total net intensities
of IL-1 protein bands in all of the supernatant samples for a given blot.
Preparation of ELISA supernatants
BMDM (1105) were plated/well of 24-well plates overnight in IMDM. The
next day, the spent media were removed, and BMDM were primed with 1
ug/ml LPS for 4 h. LPS was then removed, and 300 l of the indicated
treatments was added for the indicated times. As TLO pore-forming activity
is inhibited by free cholesterol present in FBS, TLO treatments were added in
IMDM lacking FBS for 5 min, followed by addition of 10% FBS. Cholesterol
inhibition of TLO activity was conducted by pre-mixing 1 ug/ml free choles-
terol with TLO before addition to cells. For all other inhibitor experiments,
inhibitors were preincubated with BMDM for 1 h after LPS removal prior to
the addition of TLO, ATP, or nigericin. Inhibitors were prepared in serum-
free IMDM containing 0.01% BSA. Supernatants were collected, centrifuged
10,000 rpm for 10 min, and stored at –20°C before analysis by ELISA.
ELISA
High-bind polystyrene 96-well plates (Greiner Bio-One, Monroe, NC, USA)
were coated with 100 l/well 1 g/ml purified anti-mouse IL-1, 4 g/ml
purified anti-mouse IL-1, or 1 purified anti-mouse TNF- capture anti-
body overnight. Wells were washed three times with 200 l/well wash
buffer (0.05% Tween 20 in PBS), and this step was repeated in between
each of the following incubations: 200 l/well filtered 1% BSA in PBS for
1 h at room temperature; 100 l/well standards or supernatant samples for
2 h at room temperature; 100 l/well 1 g/ml biotinylated anti-mouse IL-
1, 6 g/ml biotinylated anti-mouse IL-1, or 1 biotinylated anti-mouse
TNF- detection antibody for 1 h at room temperature; 100 l/well 1:5000
avidin-HRP for 30 min at room temperature; 100 l/well TMB substrate
for 10 min (IL-1, TNF-) or 20 min (IL-1) at room temperature; and 50
l/well 1 M sulfuric acid to stop the reaction. OD values were read at 450
nm with a 570-nm subtracted correction using a BioTek PowerWave™ XS
microplate spectrophotometer, and data were analyzed using Gen5™ data
analysis software (BioTek Instruments, Inc. Winooski, VT, USA).
LDH release assay
BMDM (4.5105) were plated/35 mm dish overnight in IMDM. The next
day, spent media were removed, and BMDM were treated with 1 ug/ml
LPS for 4 h. Cells were then washed with PBS and incubated for 30 min
with DTT control buffer or various TLO concentrations in phenol red-free
IMDM. Triton X-100 (1%) was used as a control of complete cell lysis and
maximal LDH release. Supernatants were collected and assayed in duplicate
for LDH content using the LDH cytotoxicity assay kit from Cayman Chemical
Co. (Ann Arbor, MI, USA). Percent cytotoxicity was calculated as follows:
[(mean OD value of experimental sample–mean blank OD)/(mean OD value
of Triton X-100 control sample–mean blank OD)]  100. BMDM from these
experiments were harvested from dishes using CellStripper™ (Mediatech,
Inc.) and stained with 5 M YO-PRO-1 dye (Invitrogen) before analysis using a
BD Biosciences (San Jose, CA, USA) LSR II flow cytometer and accompanying
FACSdiva™ software. BMDM were also stained with YO-PRO-1 after 5 min of
DTT control buffer or TLO treatments.
Cy5 labeling of toxin
A monofunctional N-hydroxysuccinimide-ester Cy5 (GE Healthcare, Piscat-
away, NJ, USA) vial was resuspended in 20 l PBS and diluted 1:100. TLO
(2.5 g; 2.5 l) or 2.5 g BSA control (2.5 l) was labeled with 0.5 l PBS
(control, unlabeled TLO) or 0.5 l 1:100 Cy5 (TLO-Cy5) for 10 min at
room temperature in the dark. To quench each reaction, 2.5 g BSA was
added and incubated for 10 min at room temperature in the dark.
Toxin binding and pore formation flow cytometry
assay
BMDM (4.5105) were plated/35 mm petri dish overnight in IMDM. The
next day, spent media were removed, and BMDM were treated with 1
ug/ml LPS for 4 h. LPS was then removed, and 1 ml each indicated inhibi-
tor was added for 1 h. Inhibitors were prepared in serum-free IMDM con-
taining 0.01% BSA. Then, TLO, TLO-Cy5, or BSA-Cy5 was added to cells in
the presence or absence of 1 g/ml cholesterol for 5 min. Cells were har-
vested from dishes and stained with 5 M YO-PRO-1 dye before analysis by
flow cytometry. FlowJo (Tree Star, Inc., Ashland, OR, USA) was used for
data analysis. A similar protocol was followed for BMDM treated with unla-
beled TLO in the presence or absence of 1 g/ml cholesterol.
Live cell microscopy
BMDM (1105) were plated/35 mm collagen-coated glass-bottom culture
dish (MatTek Corp., Ashland, MA, USA) overnight in IMDM. The next
day, cells were primed with 1 g/ml LPS for 4 h. Cells were washed with
serum-free IMDM and incubated for 15 min with 0.5 M LysoTracker™
Green in serum-free IMDM. BMDM were treated with a final concentration
of 1.8 nM TLO-Cy5 in serum-free media. In indicated experiments, TLO-
Cy5 was preincubated with 1 g/ml cholesterol before addition to cells.
Live cell imaging was performed using a Nikon TI inverted microscope
with a 60 1.49-NA oil immersion optic, a NikonPiezo-driven XYZ stage, a
Prairie Sweptfield confocal head, and a Prairie Technology (Madison, WI,
USA) laser bench. Images were collected using a QuantEM back-thinned
512B camera (Photometrics, Tucson, AZ, USA). Cells were maintained at
37°C in the microscope with a Tokai Hit environmental stage (Tokyo, Ja-
pan). Software control of the microscope was with Elements (Nikon,
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Melville, NY, USA). Data analysis was performed using Metamorph soft-
ware.
Graphical and statistical analysis
All graphing analyses were completed using Microsoft Excel (Microsoft,
Redmond, WA, USA). Statistical analysis (Student’s paired t-test) was con-
ducted with GraphPad Prism (GraphPad Software, Inc., San Diego, CA,
USA). P values were denoted as follows: *, P  0.05; **, P  0.01; P 
0.05  not significant.
RESULTS
TLO-induced IL-1 release occurs via a mechanism
distinct from TLR activation
Previous studies reporting IL-1 induction by CDC did not fully
characterize the mechanism involved. As CDC have been re-
ported to activate TLR4 [43–47], we considered whether non-
lytic doses of TLO could prime BMDM to synthesize pro-IL-1
similarly to LPS. Release of IL-1 might be expected to occur
at low levels following such treatment, particularly if some cell
death occurred over the time course of the experiment. To
test this, Western blotting was first used to measure pro-IL-1
levels in lysates of cells exposed to varying doses of TLO or 1
g/ml LPS. At all concentrations of TLO tested, after a 4-h
period, no pro-IL-1 could be detected, and large amounts
were induced by LPS (Fig. 1). In addition, there was little to
no detectable release of IL-1 from TLO-primed cells over this
4-h time period, as measured by a sensitive ELISA assay to test
culture supernatants (detection limit, 16 pg/ml; data not
shown). Thus, TLO cannot replace LPS for the priming of
cells to synthesize pro-IL-1.
We next tested if LPS-primed cells could release IL-1 after
exposure to TLO. A time course of IL-1 (Fig. 2A) as well as
IL-1 (Fig. 2B) release demonstrates the rapid rates at which
these cytokines are exported after TLO exposure, with near-
maximal secretion seen by 2 h. Nonprimed BMDM, as well as
cells exposed to TLO for 4 h without LPS, could not be in-
duced to secrete IL-1 following addition of TLO, ATP, or ni-
gericin (data not shown). This rapid secretion contrasts to the
release of another proinflammatory cytokine, TNF-, from
LPS-primed BMDM, which have been exposed to control
buffer, TLO, ATP, or nigericin for up to 2 h (Fig. 2C). LPS
priming induces background levels of TNF-, as seen for the
control, but additional treatment with TLO, ATP, or nigericin
does not raise these levels significantly above background.
These results are consistent with TLO acting to induce rapid
release of IL-1 and IL-1 and suggest that this occurs inde-
pendently of TLR activation. The kinetics of the response was
similar to those for ATP and nigericin, suggesting possible
mechanistic similarities.
Pore formation is required for TLO-induced IL-1
secretion
To further address the mechanism of CDC-induced cytokine
release, we determined whether TLO pore formation was re-
quired to induce IL-1 release. Free cholesterol was added to
TLO at a concentration shown previously to inhibit its ability
to bind cholesterol on cell membranes and subsequently form
pores [13]. Cholesterol-inhibited TLO was not able to induce
IL-1 release from BMDM (Fig. 3). To confirm that pore for-
mation was blocked under these conditions, uptake of YO-
PRO-1 dye, which does not cross intact cell membranes but
readily enters permeabilized cells [29, 48], was measured (Fig.
3, inset). Thus, TLO-induced pore formation is required for
the release of IL-1.
Lower TLO doses are required for the release of
mature IL-1
A straightforward explanation for the above results might be
that TLO exposure could passively lead to release of IL-1
from BMDM through toxin-induced pores. To begin to test
this possibility, toxin-induced pore formation in BMDM mem-
branes, measured by YO-PRO-1 uptake, was compared with
toxin-induced, passive spilling of intracellular contents, as mea-
sured by LDH release. BMDM became perforated within 5 min
of treatment by even the lowest dose of TLO tested (0.9 nM
TLO), and the percentage of cells perforated increased in a
dose-dependent manner (Fig. 4A). These cells appeared to
undergo membrane recovery by 30 min post-treatment, as dye
uptake did not change from background for all TLO concen-
trations tested (Fig. 4B). Significant LDH release was not evi-
dent until exposure of BMDM to a much higher dose of 18.3
nM TLO (Fig. 4C). Thus, it appears that although cells be-
come perforated starting at low levels of toxin, a high thresh-
old of toxin must be reached before passive release of intracel-
lular components occurs. IL-1 release in response to varying
concentrations of TLO was then measured by ELISA (Fig. 4D).
Maximal secretion of IL-1 occurred at 9.1 nM, a concentra-
tion that resulted in 10% LDH release. Strikingly, high levels
of TLO, which resulted in correspondingly higher LDH re-
lease, induced lower levels of IL-1 secretion.
We next determined whether IL-1 released from cells was
processed to the mature bioactive form by analyzing superna-
tants using Western blotting. A majority of the IL-1 was fully
processed in supernatants from cells treated with 1.8 nM TLO,
Figure 1. TLO cannot replace LPS as signal 1. BMDM
were treated with control (DTT-containing buffer), 1 g/ml
LPS, 1.8 nM TLO (100 ng/ml TLO), 4.6 nM TLO (250
ng/ml TLO), 9.1 nM TLO (500 ng/ml TLO), or 18.3 nM
TLO (1 g/ml TLO) for 4 h in serum-containing media.
Lysates were prepared from these cells, 50 g protein run
on a SDS-PAGE gel, and Western blot conducted for IL-1
protein. Only LPS treatment induces the detectable expres-
sion of 35 kDa pro-IL-1. Data shown are a representative
example of two independent experiments.
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whereas in supernatants from cells treated with 9.1 nM or 18.3
nM TLO, much of the IL-1 was in the pro-form, and a less-
mature form was detected (Fig. 5A). We also confirmed that 3
mM ATP and 20 M nigericin induced the release of mostly
mature IL-1 and 1% Triton X-100 lysed cells for complete
release of pro-IL-1 content. As caspase-1 is known to cleave
pro-IL-1 to its mature form and undergo cleavage and release
itself after activation, we further tested for release of the p20
caspase-1 cleavage product after exposure to TLO. Mature p20
caspase-1 release only occurred at the low 1.8-nM TLO dose,
and pro-caspase-1 was released from cells treated with high 9.1
nM or 18.3 nM TLO doses (Fig. 5B). ATP and nigericin con-
trols also induced caspase-1 cleavage, but mature caspase-1
stayed inside the cells after ATP treatment, and nigericin treat-
ment induced most of it to be secreted from the cells. Triton
X-100 caused complete lysis and release of pro-caspase-1 stores.
We found the same pattern of IL-1 content in these samples
as shown in Figure 4D (data not shown). Thus, cleavage of
pro-caspase-1 for release of mature caspase-1 and secretion of
mature bioactive IL-1 by BMDM occur selectively at concen-
trations of toxin that are essentially nonlytic.
IL-1 induced by low doses of TLO requires potassium
efflux, calcium influx, and the activities of calcium-
independent PLA2, caspase-1, and cathepsin B
To further elucidate the mechanism of IL-1 secretion in-
duced by sublytic doses of TLO, we used a pharmacologic ap-
proach to inhibit different processes known to play a role in
IL-1 secretion induced by other stimuli. Potassium efflux
from cells, shown to be important for ATP and nigericin-in-
duced IL-1 release, can be inhibited by addition of excess
exogenous KCl to the medium. Figure 6A demonstrates that
KCl also inhibited IL-1 release induced by TLO. It has also
been shown that IL-1 secretion induced by ATP requires cal-
cium influx. Treatment of BMDM with intracellular calcium
chelator BAPTA-AM (Fig. 6B) prior to TLO exposure blocked
IL-1 secretion similarly to that for ATP and nigericin. An-
other event that occurs during ATP-induced IL-1 release is
Figure 2. LPS-primed BMDM treated with TLO rapidly release
IL-1 and IL-1. (A) IL-1 and (B) IL-1 content in supernatants
from 4 h LPS-primed BMDM treated with control (DTT-containing
buffer), 1.8 nM TLO, 3 mM ATP, and 20 M nigericin for 20 min,
30 min, 2 h, or 20 h was measured by ELISA. The majority of
IL-1 and IL-1 is released by 2 h post-treatment. Data represent
mean  sem for three independent experiments each for IL-1
and IL-1. (C) TNF- content in supernatants from 4 h LPS-
primed BMDM treated with control (DTT-containing buffer), 1.8
nM TLO, 3 mM ATP, and 20 M nigericin for 20 min or 2 h was
measured by ELISA. Significant levels of TNF- are not induced by
TLO, ATP, or nigericin above control background levels. Data rep-
resent mean  sem for three independent experiments.
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the activation of iPLA2, which is also involved in TLO-induced
IL-1 secretion, as tested by the iPLA2 inhibitor BEL (Fig. 6C).
Lastly, ion fluxes and iPLA2 activity are thought to be involved
in the activation of caspase-1, which in turn, cleaves pro-IL-1
to the mature form before its release. Pan-caspase inhibitor
z-VAD-fmk and caspase-1-specific inhibitor Ac-YVAD-cmk each
inhibited TLO-induced IL-1 secretion (Fig. 6D). Similar inhi-
bition was seen with ATP and nigericin controls. All of the above
pharmacological inhibitors were tested for toxicity against BMDM
using YO-PRO-1 dye uptake (data not shown). It was found that
BMDM exposed to 50 mM KCl, 30 M BAPTA-AM, 10 M BEL,
20 M z-VAD-fmk, 100 M Ac-YVAD-cmk, 100 M pepstatin A,
100 M CA-074-Me, or 10 M Z-FF-fmk for 1 h did not take up
YO-PRO-1 above background levels observed for untreated
BMDM. Thus, the inhibitors used at these concentrations were
not toxic to BMDM. Overall, these results demonstrate that sub-
lytic TLO doses induce IL-1 secretion through similar mecha-
nisms of that for ATP and nigericin.
It was reported recently that IL-1 released from cells ex-
posed to silica and alum crystals, and also amyloid- fibrils,
required cathepsin B activity [35, 37]. Both groups proposed
the novel hypothesis that cathepsin B localization to the cy-
tosol might participate in IL-1 processing. We therefore in-
vestigated the role of cathepsin B activity in toxin-induced
IL-1 release by using the highly selective cathepsin B inhibi-
tor CA-074-Me. IL-1 release induced by a low dose of TLO
was blocked substantially by this inhibitor (Fig. 6E). We also
tested the contribution of other cathepsins in IL-1 release by
using specific inhibitors pepstatin A (Fig. 6E) and Z-FF-fmk
(Fig. 6F) to inhibit cathepsin D and cathepsin L activities, re-
spectively. Little if any effect on TLO-induced IL-1 was ob-
served with these inhibitors, suggesting that cathepsin D and L
do not participate in toxin-induced cytokine release. ATP and
nigericin showed a similar dependence on cathepsin B, with a
partial contribution of cathepsin L evident for both of these
stimuli. These results demonstrate that cathepsin B activity is
required for release of IL-1 induced by sublytic TLO doses.
TLO-induced mature IL-1 release is dependent on
the NLRP3 inflammasome
As ion fluxes, iPLA2, caspase-1, and the release of IL-1 have
all been linked to inflammasome activation, specifically, the
NLRP3 inflammasome, we sought to determine if NLRP3
played a role in TLO-induced IL-1 secretion. To test this, we
compared the response of wild-type, NLRP3-deficient, and
NLRC4-deficient BMDM to a low dose of TLO (1.8 nM). We
observed that 1.8 nM TLO induced mature IL-1 release from
LPS-primed wild-type BMDM as well as NLRC4/ BMDM but
not NLRP3/ BMDM (Fig. 7A). Similar results were obtained
with the nigericin control, and Triton X-100 lysis caused re-
lease of pro-IL-1, regardless of a NLRC4 or NLRP3 defi-
ciency. Furthermore, a high dose of TLO (18.3 nM) induced
release of the pro form from wild-type and NLRP3/ BMDM
(Fig. 7B). Taken together, these results demonstrate NLRP3
dependence for mature IL-1 release caused by a low dose of
TLO but NLRP3 independence for pro-IL-1 secretion after
exposure to a high TLO dose.
Toxin-induced pore formation is necessary but not
sufficient for IL-1 release
We hypothesized, based on the above results, that pore formation
would not be sufficient to induce IL-1 release by TLO in the
absence of other components of the signaling pathway we identi-
fied. First, we assessed the ability of toxin to bind BMDM in the
presence and absence of cholesterol using live cell confocal imag-
ing to characterize the interaction. Cy5-labeled TLO was gener-
ated for this purpose, and BMDM were labeled with Lyso-
Tracker™ Green as a marker of internal compartments. Active
TLO-Cy5 (noncholesterol-treated) bound predominantly to the
surface of BMDM (Fig. 8A). On the other hand, BMDM internal-
ized cholesterol-bound TLO-Cy5 to mostly nonacidic compart-
ments, as there was little colocalization observed with Lyso-
Tracker™ Green-labeled vesicles (Fig. 8B). To next test if bind-
ing and pore formation could occur in the presence of inhibitors
of IL-1 release, the interaction between Cy5-labeled TLO and
BMDM was measured by flow cytometry. Pore formation was
measured by uptake of YO-PRO-1 dye. Fluorescently labeled TLO
binds to cells and perforates them, as evidenced by increased YO-
PRO-1 uptake (Fig. 8C) and increased Cy5 signal (Fig. 8D), rela-
tive to cells exposed to labeled BSA used as a control. In the
presence of BAPTA-AM or KCl, which impairs IL-1 secretion as
discussed previously, binding of TLO and subsequent pore for-
mation are essentially unaffected. It can again be seen that Cy5-
Figure 3. TLO-induced pore formation is required for IL-1 release
from BMDM. Four-hour LPS-primed BMDM were treated with con-
trol (DTT-containing buffer), control plus 1 g/ml cholesterol, 1.8
nM TLO, or 1.8 nM TLO plus 1 g/ml cholesterol for 20 min, 30
min, 2 h, or 20 h. Supernatants were collected and assayed by
ELISA for IL-1. Free cholesterol inhibits TLO-induced IL-1 re-
lease. Data represent mean  sem for three independent experi-
ments. Student’s paired t-test was applied for comparison of the
1.8-nM TLO group with cholesterol versus without cholesterol; *,
P  0.05; **, P  0.01. (Inset) Four-hour LPS-primed BMDM were
treated with DTT control buffer or 1.8 nM TLO in the presence or
absence of 1 g/ml cholesterol for 5 min. TLO-induced perfora-
tion as measured by YO-PRO-1 dye uptake was assessed by flow cy-
tometry. Free cholesterol blocks TLO from forming pores and al-
lowing dye uptake. Data represent mean  sem for two indepen-
dent experiments.
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labeled TLO preincubated with cholesterol associates with
BMDM, despite the lack of pore-forming activity. Taken together
with the microscopy data, these results show that cholesterol-
bound TLO can be internalized efficiently by BMDM without
causing deleterious effects and without inducing biological re-
sponses such as IL-1 secretion. Overall, these results demon-
strate that TLO-induced pore formation is required but not suffi-
cient for IL-1 release from BMDM.
DISCUSSION
We show here that TLO, a toxin of the CDC family, induces
the rapid release of IL-1 from LPS-primed murine BMDM.
Release of this cytokine typically requires two stimuli: TLR
pathway activation to generate the inactive IL-1 precursor and a
stimulator of the inflammasome for the activation of caspase-1 to
cleave pro-IL-1 to its mature form before release. It has been
observed that signal 1 (e.g., LPS) alone or signal 2 (e.g., ATP)
alone stimulates IL-1 release from macrophages at low levels
(pg/ml range for in vitro cultures), usually over long time peri-
ods (up to 24 h) [47, 49]. However, when both signals are ap-
plied sequentially, IL-1 can be secreted from macrophages in
large amounts (ng/ml range) within 30 min [28, 50]. Our results
are consistent with TLO acting as a type of signal 2 and are in-
consistent with TLO providing signal 1 to BMDM.
Shoma et al. [47] reported recently that the CDC PLY in-
duced the release of IL-1 and IL-1 from murine peritoneal
macrophages, a TLR4-dependent process not inhibited by cho-
lesterol [47]. The PLY doses used in those experiments were
similar to those for TLO used in our experiments. Addition-
ally, other groups have found that PLY induces IL-1 secretion
from monocytes [20] and that CDC LLO induces IL-1 (type
not defined) release from peritoneal macrophages [51], a pro-
cess also unaffected by free cholesterol. In contrast, we tested
whether TLO could induce release of IL-1 from LPS-primed
BMDM, which carry pre-formed stores of the cytokine. Our
results demonstrate that TLO-induced pore formation, requir-
ing binding of the toxin to cellular cholesterol, stimulates the
Figure 4. Determination of sublytic versus lytic CDC doses. (A and B) Four-hour LPS-primed BMDM were treated with DTT control buffer or a
range of TLO doses in serum-free media for 5 min or 30 min. BMDM were harvested and stained with YO-PRO-1 dye as a measure of TLO-in-
duced perforation, and dye uptake was assessed by flow cytometry. BMDM are perforated after 5 min of exposure to 0.9 nM TLO, and this process
occurs in a dose-dependent manner. By 30 min post-TLO treatment, BMDM are no longer perforated. Data represent mean  sem for three inde-
pendent experiments for each time-point. (C) Supernatants were collected from 4 h LPS-primed BMDM treated for 30 min with DTT control
buffer or various TLO doses in serum-free media. TLO-induced passive spilling of contents (i.e., LDH) was determined by taking the ratio of LDH
released from TLO-treated BMDM to LDH released from Triton X-100-treated BMDM (see Materials and Methods). In comparison with perfora-
tion at lower doses of TLO, BMDM do not release LDH until much higher doses (18.3 nM) of TLO. Data represent mean  sem for three inde-
pendent experiments. Student’s paired t-test was applied for comparison of control versus TLO conditions; **, P  0.01. (D) Four-hour LPS-
primed BMDM were treated with a range of concentrations of TLO for 30 min. Supernatants were collected and assayed by ELISA for IL-1. Re-
lease of IL-1 from BMDM occurs after treatment with 0.9–36.5 nM TLO. Data represent mean  sem for three independent experiments.
Chu et al. Bacterial toxin-mediated IL-1 release
www.jleukbio.org Volume 86, November 2009 Journal of Leukocyte Biology 1233
rapid release of large amounts of cytokine through a mecha-
nism dependent on K	 efflux, Ca2	 influx, and the activation
of iPLA2, NLRP3, caspase-1, and cathepsin B. It should be
noted that there was some variation in the amounts of TLO-
induced IL-1 (mean amount/experiment ranged from 1975
to 3973 pg/ml; minimum803 pg/ml; maximum7569 pg/
ml). The spread in values is most likely a result of several fac-
tors, such as differences in macrophage batch preparation,
macrophage harvest day (as BMDM were maintained in cul-
ture up to 3 weeks), sample collection day, and assay day.
It appears that TLO-induced pore formation causes K	 ef-
flux and subsequent IL-1 release. However, mature IL-1 re-
lease only occurs when pore formation is balanced by the abil-
ity of cells to maintain function, required presumably for the
activation of appropriate signaling pathways that will lead to the
activation of caspase-1, the protease responsible for the conver-
sion of inactive pro-IL-1 to active, mature IL-1. Evidence for
this is seen at low concentrations of TLO, which induced release
of primarily mature IL-1 as well as cleaved, mature caspase-1,
whereas higher doses caused release of the pro-forms of caspase-1
and IL-1 predominantly, which are biologically inactive. We sug-
gest that at high concentrations of toxin, a cell may undergo
rapid release of contents (e.g., pro-caspase-1 and pre-formed pro-
IL-1 stores) through a passive process, outpacing the ability of
the cell to activate caspase-1, required for processing of the pro-
to mature form. This finding may explain a difference between
our results and those of Kanneganti et al. [31], who reported
that CDC SLO does not activate caspase-1. In their study, SLO
was used at a high dose of 5 g/ml or 72.5 nM.
In addition to a requirement for K	 efflux, we identified calcium
influx and the activities of iPLA2, NLRP3, and caspase-1 as key play-
ers in TLO-induced IL-1 release. To our knowledge, this is the first
study to address the mechanism of CDC-induced IL-1 release and
to differentiate the effects of low versus high toxin doses. Noncholes-
terol binding, PFTs from other families, such as Aeromonas hydrophila
aerolysin, which binds to GPI-anchored protein receptors, and
Staphylococcus aureus -toxin, which binds specific lipid clusters
[52], have also been shown to require K	 efflux for their down-
Figure 5. Lower concentrations of TLO are required to elicit mature IL-1
release from BMDM. (A) Four-hour LPS-primed BMDM were treated with
control (DTT-containing buffer), 1.8 nM, 9.1 nM, and 18.3 nM doses of TLO,
3 mM ATP, 1% Triton X-100, and 20 M nigericin for 30 min in serum-free
IMDM. Whole cell protein lysate (20 g) or entire 1 ml TCA/cholic acid-pre-
cipitated supernatants were run on a SDS-PAGE gel and Western blot con-
ducted for mature IL-1 (mIL-1; 17 kDa) or pro-IL-1 (35 kDa) protein.
Supernatants from 1.8 nM TLO-treated BMDM contain mostly mature IL-1,
and 9.1 nM and 18.3 nM TLO-treated BMDM supernatants contain mostly
pro-IL-1. ATP and nigericin controls induce the release of mostly mature
IL-1, and Triton X-100 lyses cells for release of pro-IL-1. Data shown in the
left panels are representative examples of three independent experiments.
The right panels show the densitometry (see Materials and Methods) of the
pro- and mature IL-1 bands in supernatants expressed as mean percent of
total IL-1 in supernatants  sem for three independent experiments. (B) BMDM were treated as in part A. Whole cell protein lysate (20 g)
or entire 1 ml TCA/cholic acid-precipitated supernatant was run on a SDS-PAGE gel and Western blot conducted for pro-caspase-1 (45 kDa) or
the cleaved p20 caspase-1 subunit (20 kDa). Supernatants from 1.8 nM TLO-treated BMDM contain mostly p20 caspase-1, and 9.1 nM and 18.3
nM TLO-treated BMDM supernatants contain pro-caspase-1. ATP and nigericin controls induce the cleavage of pro-caspase-1 with release of the
p20 subunit from nigericin-treated cells and retained p20 for ATP-treated cells. Triton X-100 lyses cells for release of pro-caspase-1. Data shown
are a representative example of two independent experiments.
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stream effects [53–55]. Aerolysin has been implicated in the activa-
tion of the NLRP3 and NLRC4 inflammasomes as well as caspase-1
for the activation of sterol regulatory element-binding proteins,
which promote cell survival after cell membrane injury [53]. How-
ever, this study used nonimmune cells, and the role of aerolysin in
IL-1 processing and release was not addressed. -Toxin has also
been shown to induce IL-1 secretion from LPS-primed monocytes,
but the mechanism of release is unclear [55, 56]. It should be
stressed that although these other toxins may share some similarities
to CDC in their ability to form pores in cells and initiate K	 efflux,
they also differ in pore size (2 nm for aerolysin and -toxin; 30 nm
for CDC) [52] and therefore, could have divergent downstream
pathways. One such example is the response of cells to -toxin-medi-
ated versus CDC-mediated cell injury. It has been observed that
membrane repair after CDC-induced injury involves a p38-indepen-
dent mechanism and occurs in less than 1 h compared with -toxin-
Figure 6. TLO-induced IL-1 release from BMDM relies on K efflux, Ca2 influx, and the activities of iPLA2, caspase-1, and cathepsin B. Four-hour
LPS-primed BMDM were treated with no inhibitor (buffer only) versus 50 mM KCl (K	 efflux inhibitor; A), 30 M BAPTA-AM (intracellular calcium
chelator; B), 10 M BEL (iPLA2 inhibitor; C), 20 M z-VAD-fmk (pan-caspase inhibitor) or 100 M Ac-YVAD-cmk (caspase-1 inhibitor; D), 100 M pep-
statin A (cathepsin D inhibitor) or 100 M CA-074-Me (cathepsin B inhibitor; E), or 10 M Z-FF-fmk (cathepsin L inhibitor; F) for 1 h. Control (DTT-
containing buffer), 1.8 nM TLO, 3 mM ATP, or 20 M nigericin treatments were then added for 30 min. Supernatants were collected and assayed by
ELISA for IL-1. KCl, BAPTA-AM, BEL, z-VAD-fmk, and Ac-YVAD-cmk almost completely abrogate IL-1 secretion induced by TLO, ATP, and nigericin.
Cathepsin B inhibitor CA-074-Me has a major effect on IL-1 secretion induced by all three stimuli, and the other cathepsins play a lesser role. It should
be noted that all inhibitors were not toxic to cells, as assessed by YO-PRO-1 dye uptake (data not shown). Data represent mean  sem for (A, D, and E)
five independent experiments, (B) six independent experiments, (C) three independent experiments, and (F) four independent experiments. Student’s
paired t-test was applied for comparison of no inhibitor versus inhibitor conditions; *, P  0.05; **, P  0.01.
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mediated repair that requires p38 activity and may take many hours
for full recovery [14, 57]. Thus, it will be interesting to see if IL-1
processing and release mechanisms are similar or disparate for PFTs
that form small pores (-toxin, aerolysin) versus large ones (CDC).
Although the involvement of ion fluxes and the activities of
iPLA2, NLRP3, and caspase-1 in IL-1 release induced by ATP
and nigericin are well established [58], the mechanism for di-
rect activation of the NLRP3 inflammasome complexes has
remained unclear. Recently, studies by Hornung et al. [35]
and Halle et al. [37] have suggested that cathepsin B may acti-
vate the NLRP3 inflammasome directly or indirectly through
other factors. In their studies, they show that IL-1-inducing stim-
uli, such as silica crystals, alum salt crystals, and amyloid- fibrils,
are phagocytosed and that these cargos disrupt lysosomal integ-
rity. This would allow subsequent release of cathepsin B into the
cytosol, which is proposed to cause activation of the NLRP3 in-
flammasome by an unknown mechanism. We also observe a de-
pendence on cathepsin B activity for TLO-induced IL-1 secre-
tion. Studies are under way to determine if this toxin relies on
similar pathways as silica crystals, alum salt crystals, and amyloid-
fibrils, which lead to active cytosolic cathepsin B.
In addition to understanding how caspase-1 is activated directly
in this system, there is much interest in determining the general
mechanism by which mature IL-1 is secreted from cells. IL-1
lacks signal sequences for localization to the Golgi and other clas-
sical secretory compartments and therefore, must be secreted by
nonclassical means. The data available suggest several possible,
different pathways, including release of exosomes carrying ma-
ture IL-1 after fusion of multivesicular bodies with the plasma
membrane, Ca2	-dependent secretory lysosome exocytosis, mi-
crovesicle shedding from the plasma membrane, and direct trans-
location of cytosolic cytokine through unknown plasma mem-
brane transporters to the extracellular environment [42]. It is
possible that multiple pathways may be involved for a single cell
type or that a particular pathway is designated to each specific
cell type. At this time, it is unknown what pathway(s) TLO uses to
export mature IL-1.
This is the first study to identify the mechanism of IL-1
release induced by a family of cholesterol-binding, large PFTs
and to distinguish the IL-1 response to lower versus higher
toxin doses. This IL-1 release mechanism may differ from
that for other families of PFTs that bind different receptors,
form much smaller pores, and use different pathways to
achieve the same goal (i.e., pore-resealing processes). More-
over, to our knowledge, this is the first observation of cathep-
sin B involvement in IL-1 release induced by a PFT. In sum-
mary, we find that low TLO concentrations induce the rapid
release of relatively high amounts of active, mature IL-1 from
LPS-primed murine macrophages in a process dependent on
toxin-induced perforation, potassium efflux, calcium influx,
and activation of iPLA2, NLRP3, caspase-1, and cathepsin B.
On the other hand, high TLO doses induce the release of in-
active pro-IL-1, which may be an evasion mechanism used by
bacteria during infection. This study addresses in detail the
mechanisms of CDC-induced, rapid IL-1 release and may
Figure 7. IL-1 release induced by low TLO doses is NLRP3-dependent.
(A) Four-hour LPS-primed wild-type (WT), NLRC4/ (NLRC4 KO), or
NLRP3/ (NLRP3 KO) BMDM were treated with control (DTT-containing
buffer), 1.8 nM TLO, 20 uM nigericin, or 1% Triton X-100 for 30 min in serum-free IMDM. Whole cell protein lysate (20 g) or entire 1 ml
TCA/cholic acid-precipitated supernatants were run on a SDS-PAGE gel and Western blot conducted for mature (17 kDa) or pro (35 kDa)-
IL-1 protein. Mature IL-1 was released from wild-type and NLRC4/ BMDM after exposure to the low TLO dose and nigericin but not from
NLRP3/ BMDM. Triton X-100 lysis caused release of pro-IL-1 stores from all cell types, including NLRP3/ BMDM. Data shown are repre-
sentative examples of two independent experiments. (B) Four-hour LPS-primed wild-type or NLRP3/ BMDM were treated with control (DTT-
containing buffer), 1.8 nM TLO (low dose), 18.3 nM TLO (high dose), or 1% Triton X-100 for 30 min in serum-free IMDM. Whole cell pro-
tein lysate (20 g) or entire 1 ml TCA/cholic acid-precipitated supernatants were run on a SDS-PAGE gel and Western blot conducted for ma-
ture (17 kDa) or pro (35 kDa)-IL-1 protein. Mature IL-1 was released from wild-type BMDM after exposure to the low TLO dose but not
from NLRP3/ BMDM. The high TLO dose as well as Triton X-100 caused release of pro-IL-1 stores from wild-type and NLRP3/ BMDM.
Data shown are a representative example of three independent experiments.
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help to explain the effects of these toxins in bacterial infec-
tions and the subsequent host immune responses.
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